Perfusion and Process Intensification Patents: Leaders & Trends 2026
Perfusion and Process Intensification Patents: Who Leads and Where Filing Is Heading
35.7% of all 4,506 records sit with just five assignees, so most of the claim space around cell retention and perfusion control is already staked out by a small group. Annual filings rose from 205 in 2017 to a peak of 322 in 2021, then declined to 215 by 2024 — a 33% drop over that three-year span. Volumes in 2025 and 2026 appear lower still, but that reflects publication lag rather than a real collapse in activity; those years are not yet complete in the record.
- 1AMGEN INC17.1%
- 2GENZYME CORP6.1%
- 3F HOFFMANN LA ROCHE & CO AG4.6%
- 4WYETH LLC4.0%
- 5GENENTECH INC3.9%
See the full perfusion and process intensification analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in perfusion and process intensification?
One assignee leads the ranked field with 772 records, well ahead of the fifth-place holder at 174 and the tenth-place holder at 90. The top five assignees combined account for 35.7% of all 4,506 records in scope, and the top ten reach 47.4%. This concentration means a small group of established biologics manufacturers controls most of the core claim space around cell retention and perfusion control methods.
Is filing activity in this field growing or shrinking?
Filings rose from 205 in 2017 to a peak of 322 in 2021, then fell to 215 by 2024 — a 33% decline over that three-year span, which is the last period the dataset treats as complete. Numbers for 2025 and 2026 look lower still, but that reflects the roughly 18-month lag between filing and publication rather than a genuine collapse in activity. The honest read is a pullback from a 2021 peak, not a dying field.
What technology areas dominate perfusion and process intensification patents?
C12N (microorganisms and genetic engineering) appears in 57.6% of the 4,506 records, and C07K (peptides and proteins) in 37.6%, making this a biology-first field rather than an apparatus-first one. C12M, the class covering bioreactors and enzyme apparatus, sits at 25.1% — present but secondary. Filtration-specific claims under B01D cover just 10.3% of records, which is comparatively light given how central cell retention and filter fouling are to the field’s search terms.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Perfusion and Process Intensification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.